Sutimlimab, a first-in-class humanised Ig monoclonal antibody that prevents CP activation has previously been shown to result in rapid and sustained improvements in Hb, haemolytic markers, and QoL in patients with CAD in Part A of the CADENZA and CARDINAL studies.13 This evidence concerns the gene GSTM1 and cold agglutinin disease.